AN2 Therapeutics (ANTX) Change in Account Payables (2021 - 2026)
AN2 Therapeutics' (ANTX) quarterly Change in Account Payables came in at -$405000.0 in Q1 2026, down 65.98% year-on-year from -$1.2 million in Q1 2025, and down 150.94% on a QoQ basis from $795000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Change in Account Payables (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Change in Account Payables data on file, last reported at -$405000.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables fell 65.98% year-over-year to -$405000.0 in Q1 2026; TTM through Mar 2026 was -$457000.0, a 171.41% decrease from a year earlier, with the FY2025 full-year figure at -$296000.0, down 146.18% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$405000.0, down from $795000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for ANTX reached as high as $1.7 million in Q3 2023 and fell as low as -$2.1 million in Q4 2023.
- Historically, Change in Account Payables has averaged $175882.4 across 5 years, with a median of -$171000.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 1065.5% in 2023 and fell as far as 409.4% in 2023.
- Year by year, Change in Account Payables stood at $681000.0 in 2022, then plunged by 409.4% to -$2.1 million in 2023, then surged by 176.22% to $1.6 million in 2024, then sank by 50.5% to $795000.0 in 2025, then sank by 150.94% to -$405000.0 in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$405000.0 in Q1 2026, $795000.0 in Q4 2025, and $113000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | -405,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -405,000.00 |
| Mar 31, 2026 | -405,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Jun 30, 2025 | -960,000.00 |
| Jun 30, 2025 | -960,000.00 |
| Mar 31, 2025 | -244,000.00 |
| Mar 31, 2025 | -244,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | -174,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Jun 30, 2024 | -548,000.00 |
| Jun 30, 2024 | -548,000.00 |
| Mar 31, 2024 | -243,000.00 |
| Mar 31, 2024 | -243,000.00 |
| Dec 31, 2023 | -2.11 Mn |
| Dec 31, 2023 | -2.11 Mn |